Data from the Rainbowfish trial was presented at the World Muscle Society (WMS) Congress 2024 in Prague, Czech Republic.

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's NMPA for a specific type of NSCLC.

Inventiva will gain a new chairman following the deal as it presses ahead with a Phase III trial for its lead asset.

Capricor Therapeutics plans to apply for FDA approval for its DMD cell therapy, deramiocel, by the end of 2024.

Sanofi has announced negotiations with Clayton Dubilier & Rice (CD&R), regarding the potential sale of a 50% controlling ...

Pfizer has announced the approval of HYMPAVZI by the US Food and Drug Administration (FDA) for patients with haemophilia A ...

RHEACELL has been researching ABCB5-positive stem cell therapies for patients with severe immune and inflammation-related ...

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

XtalPi's AI biologics discovery platform, XtalFold, has been licensed to Janssen Biotech for advanced biotherapeutics ...

The deal allows MSD to license one or more therapies against inflammatory diseases developed using the UK biotech’s ...

At CPHI Europe, an expert discussed the promise of gummies as a drug delivery system and their unique manufacturing ...

Booster Therapeutics has announced its inception to develop a new class of proteasome activator medicines for ...